SOURCE: GlobeImmune, Inc.

January 03, 2007 12:36 ET

GlobeImmune CEO to Present at JPMorgan Healthcare Conference

LOUISVILLE, CO -- (MARKET WIRE) -- January 3, 2007 -- GlobeImmune, Inc. announced today that President and Chief Executive Officer, Timothy C. Rodell, M.D., will present at the JPMorgan Healthcare Conference at the Westin St. Francis Hotel in San Francisco at 9:30 a.m. PST on Thursday, January 11, 2007.

About GlobeImmune, Inc.

GlobeImmune is a biopharmaceutical company pioneering the discovery, development, and manufacturing of potent, targeted molecular immunotherapies called Tarmogens® for the treatment of cancer and infectious diseases. GI-5005, GlobeImmune's lead product for the treatment of chronic hepatitis C infection, is currently finishing a phase 1b trial in which interim data for the first four dose cohorts have been analyzed and show both safety and positive clinical responses. Additionally, GI-4000 for the treatment of mutated Ras-mediated cancers is currently in a phase 2 clinical trial for the treatment of pancreas cancer.

About Tarmogens

Tarmogens® (Targeted molecular immunogens) are whole, heat-killed S. cerevisiae yeast, genetically modified to express high concentrations of one or more disease-related proteins. Tarmogens are designed to reprogram the human immune system to eliminate disease cells by linking the body's innate immune response (a non-specific danger response) with an antigen-specific T cell response. Because Tarmogens look dangerous to the immune system, they initiate a chain of events that end with presentation of disease-specific antigens and activation of both helper and killer T cells. The Tarmogen platform has been shown to be active and well tolerated in clinical trials in both cancer and infectious disease.

For additional information, please visit the company's website at

The anticipated presentation will contain forward-looking statements that involve significant risks and uncertainties, including statements relating to the efficacy of the Company's technology and initiation, progress, and results of the Company's clinical trial programs. Actual results could differ materially from those projected and the Company cautions readers not to place undue reliance on the forward-looking statements contained in the presentation.

Contact Information


    Kirk Christoffersen
    Senior Director, Corporate Development
    GlobeImmune, Inc.
    T: 303-625-2700
    C: 303-775-7666
    Email Contact